将自然杀伤细胞用于实体癌免疫治疗。
Weaponizing natural killer cells for solid cancer immunotherapy.
作者信息
Wong Joshua K M, Dolcetti Riccardo, Rhee Handoo, Simpson Fiona, Souza-Fonseca-Guimaraes Fernando
机构信息
The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia.
The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia; Department of Microbiology and Immunology, The University of Melbourne, Victoria 3010, Australia.
出版信息
Trends Cancer. 2023 Feb;9(2):111-121. doi: 10.1016/j.trecan.2022.10.009. Epub 2022 Nov 12.
Enhancing natural killer (NK) cell-based innate immunity has become a promising strategy for immunotherapy against hard-to-cure solid cancers. Monoclonal antibody (mAb) therapy has been used to activate NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC) towards solid cancers. Cancer cells, however, can subvert immunosurveillance using multiple immunosuppressive mechanisms, which may hamper NK cell ADCC. Mechanisms to safely enhance ADCC by NK cells, such as utilizing temporary inhibition of receptor endocytosis to increase antibody presentation from target to effector cells can now be used to enhance NK-cell-mediated ADCC against solid tumors. This review summarizes and discusses the recent advances in the field and highlights current and potential future use of immunotherapies to maximize the therapeutic efficacy of innate anticancer immunity.
增强基于自然杀伤（NK）细胞的固有免疫已成为针对难以治愈的实体癌进行免疫治疗的一种有前景的策略。单克隆抗体（mAb）疗法已被用于激活NK细胞介导的针对实体癌的抗体依赖性细胞毒性（ADCC）。然而，癌细胞可利用多种免疫抑制机制逃避免疫监视，这可能会阻碍NK细胞ADCC。现在可以使用通过暂时抑制受体内吞作用来增加从靶细胞到效应细胞的抗体呈递等方法来安全增强NK细胞的ADCC，从而增强NK细胞介导的针对实体瘤的ADCC。本综述总结并讨论了该领域的最新进展，并强调了免疫疗法当前和潜在的未来应用，以最大限度地提高固有抗癌免疫的治疗效果。
Zotero 插件